SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ziopharm
ZIOP 0.866-0.9%Jan 26 3:00 PM EDT
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: The Ox2/12/2013 9:09:10 AM
   of 14
 
7:13AM ZIOPHARM reports Phase 3 trial of ZIOPHARM'S palifosfamide in first-line metastatic soft tissue sarcoma reaches target number of progression-free survival events ( ZIOP) 3.99 : Co announces that the Phase 3 trial of palifosfamide in first-line metastatic soft tissue sarcoma has reached its target number of progression-free survival events. According to the protocol and statistical plan, reaching the target number of PFS events leads to completion of the blinded data collection process and then formal efficacy analysis by the IDMC. The co will announce topline results from this trial during the last week of March 2013.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News